Evidence map›Paper›PMID 28077131›Full record

ArticleReproductive biology and endocrinology : RB&E2017

Granulocyte colony-stimulating factor (G-CSF) promotes spermatogenic regeneration from surviving spermatogonia after high-dose alkylating chemotherapy.

Travis Kotzur, Roberto Benavides-Garcia, Jennifer Mecklenburg, Jamila R Sanchez, Matthew Reilly, Brian P Hermann

Open access · goldAbstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Transcriptional profiling of β-2MStem cell reports · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Approaches and Technologies in Male Fertility Preservation.International journal of molecular sciences · 2020
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Travis KotzurDepartment of Biology, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.
Roberto Benavides-GarciaDepartment of Biology, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.
Jennifer MecklenburgDepartment of Biology, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.
Jamila R SanchezDepartment of Biology, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.
Matthew ReillyDepartments of Biomedical Engineering and Ophthalmology, The Ohio State University, 1080 Carmack Road, Columbus, OH, 43210, USA.
Brian P HermannDepartment of Biology, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA. brian.hermann@utsa.edu.
The University of Texas at San Antonio · USThe Ohio State University · US

Funding

UTSA RISE Research Training ProgramR25GM060655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 2000 to 2022
$21.6M
UTSA Maximizing Access to Research Careers Research Training Program - Admin SupplementT34GM007717 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 1985 to 2021
$9.5M
Transcriptional regulatory networks in spermatogonial stem cellsR00HD062687 · NICHD · UNIVERSITY OF TEXAS SAN ANTONIO · PI HERMANN, BRIAN PETER · 2011 to 2013
$879k
Recruitment of New Stem Cell BiologistP30GM092334 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI MCCARREY, JOHN R · 2009 to 2010
$634k
G-CSF prevents male infertility after chemotherapy.R21HD078916 · NICHD · UNIVERSITY OF TEXAS SAN ANTONIO · PI HERMANN, BRIAN PETER · 2014 to 2015
$378k
NICHD NIH HHS R00 HD062687NICHD NIH HHS R21 HD078916NIGMS NIH HHS P30 GM092334NIGMS NIH HHS R25 GM060655NIGMS NIH HHS T34 GM007717
6 · The paper itself

Abstract

backgroundThe lifesaving chemotherapy and radiation treatments that allow patients to survive cancer can also result in a lifetime of side-effects, including male infertility. Infertility in male cancer survivors is thought to primarily result from killing of the spermatogonial stem cells (SSCs) responsible for producing spermatozoa since SSCs turn over slowly and are thereby sensitive to antineoplastic therapies. We previously demonstrated that the cytokine granulocyte colony-stimulating factor (G-CSF) can preserve spermatogenesis after alkylating chemotherapy (busulfan).

methodsMale mice were treated with G-CSF or controls before and/or after sterilizing busulfan treatment and evaluated immediately or 10-19 weeks later for effects on spermatogenesis.

resultsWe demonstrated that the protective effect of G-CSF on spermatogenesis was stable for at least 19 weeks after chemotherapy, nearly twice as long as previously shown. Further, G-CSF treatment enhanced spermatogenic measures 10 weeks after treatment in the absence of a cytotoxic insult, suggesting G-CSF acts as a mitogen in steady-state spermatogenesis. In agreement with this conclusion, G-CSF treatment for 3 days before busulfan treatment exacerbated the loss of spermatogenesis observed with G-CSF alone. Reciprocally, spermatogenic recovery was modestly enhanced in mice treated with G-CSF for 4 days after busulfan. These results suggested that G-CSF promoted spermatogonial proliferation, leading to enhanced spermatogenic regeneration from surviving SSCs. Similarly, there was a significant increase in proportion of PLZF+ undifferentiated spermatogonia that were Ki67+ (proliferating) 1 day after G-CSF treatment.

conclusionsTogether, these results clarify that G-CSF protects spermatogenesis after alkylating chemotherapy by stimulating proliferation of surviving spermatogonia, and indicate it may be useful as a retrospective fertility-restoring treatment.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingBusulfanCell ProliferationCell SurvivalDose-Response Relationship, DrugFluorescent Antibody TechniqueGranulocyte Colony-Stimulating FactorHumansKi-67 AntigenKruppel-Like Transcription FactorsMaleMice, Inbred C57BLPromyelocytic Leukemia Zinc Finger ProteinProtective AgentsRegenerationAntineoplastic Agents, AlkylatingBusulfanGranulocyte Colony-Stimulating FactorKi-67 AntigenKruppel-Like Transcription FactorsPromyelocytic Leukemia Zinc Finger ProteinProtective AgentsZbtb16 protein, mouseAdjuvantCancerFertility preservationInfertilityLate effectsSpermatogonial stem cells

Identifiers

PMID28077131
PMCPMC5225630
OpenAlexW2568384057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.